Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Volume: 376, Issue: 14, Pages: 1311 - 1320
Published: Apr 6, 2017
Abstract
High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population have raised questions about the role and timing of...
Paper Details
Title
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Published Date
Apr 6, 2017
Volume
376
Issue
14
Pages
1311 - 1320
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History